AGP Executive Report
Last update: an hour agoDental Safety & Supply Chains: Ivoclar is rolling out a verification program to help dental professionals spot authorized distributors and avoid counterfeit or gray-market dental products that can bypass quality checks and risk patient harm. Oncology Drug Deal (EU/EEA + Liechtenstein): IMPACT Therapeutics has licensed senaparib to Pharmanovia for exclusive manufacturing, development and commercialization across the EU, UK, Norway, Iceland, Switzerland and Liechtenstein (plus MENA, Australia and New Zealand), with total deal value up to €423.5M and royalties tied to sales; the drug is aimed at 1L maintenance for advanced ovarian/fallopian tube/primary peritoneal cancer. COVID-19 Vaccination Update: The European Commission authorized Pfizer-BioNTech’s XFG-adapted COVID-19 vaccine for people 6 months and older, valid across EU plus Iceland, Liechtenstein and Norway, with manufacturing already underway for the respiratory season. Travel Insurance for Older People: A guide highlights fewer insurer options and tighter age limits for seniors, with some policies covering up to 79 and a few offering no upper age cap. Schengen Politics & Health Travel Impact: Debate continues over whether an EU country could be suspended from Schengen cooperation, with Liechtenstein included in the Schengen area and potential knock-on effects for cross-border travel planning.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
